Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GENpoll: Jun 08, 2009

Reimbursing Molecular Diagnostics

Is insufficient reimbursement holding molecular diagnostic tests back from reaching the clinic?

Yes
 
  58.6%
No
 
  11.4%
Undecided
 
  30.0%

Suggest a Poll
« More Polls » « View Results »
Molecular diagnostics is one of the fastest growing areas of biotechnology product development. Once firmly rooted in the research side of the business, DNA testing is quickly making headway in the clinical arena in, for example, prenatal, tissue typing, and inherited disease applications. However, some industry analysts maintain that concern over reimbursement is acting as a roadblock to an even greater penetration of molecular diagnostic tests in the medical field. Do you agree?

Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll